Al's Comment:

 This may be a breakthrough in the treatment of Glioblastomas.  Teserpaturev is the new name for the treatment that we used to call G47 Delta.   In the clinical trial for recurrent Glioblastoma, they had a 92.3% one year survival rate, compared to historical rates of about 15%!   It should be available in Japan soon and we will work on getting it here!


Posted on: 05/25/2021

Japan to approve virotherapy drug for 1st time for cancer treatment

 


Click HERE to return to brain tumor news headlines.